ACTH Inhibitors
1 drugsAbout ACTH
Adrenocorticotropic hormone (ACTH) is a peptide hormone produced by the anterior pituitary gland. It stimulates the adrenal cortex to release cortisol, regulating metabolism, immune response, and stress. The hypothalamic-pituitary-adrenal (HPA) axis highlights its significance.
ACTH's central role in cortisol regulation makes it a therapeutic target, particularly in immunology. However, there is currently no genetic evidence directly linking ACTH to specific diseases.
ACTH is targeted by one FDA-approved drug, H.P. ACTHAR GEL, a small molecule with 8 indications. QUESTCOR PHARMA is the primary company in this space, with H.P. ACTHAR GEL approved in 2010.
Top ACTH Drugs
QUESTCOR PHARMA is the only company with an approved drug targeting ACTH.
High market concentration indicates potential entry barriers, requiring strong IP or clinical advantages for new entrants.
ACTH Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ACTH, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer differentiation and novel therapeutic approaches.
ACTH Clinical Trials 41 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ACTH. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 | 0% |
| Phase 2 | 8 | 3 | 4 | 1 | 43% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 30 | 17 | 13 | 0 | 57% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ACTH Drug Approval Timeline (2010 - 2010)
The first and only drug, H.P. ACTHAR GEL, was approved in 2010.
The stagnant approval timeline suggests a saturated market or challenges in developing new ACTH-modulating therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ACTH. A trial counts if an approved drug acting on ACTH is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.